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Background and purpose: Hypoxia is a common feature of the microenvironment of solid tumors which
has been shown to promote malignancy and poor patient outcome through multiple mechanisms. The
association of hypoxia with more aggressive disease may be due in part to recently identiﬁed links
between hypoxia and genetic instability. For example, hypoxia has been demonstrated to impede DNA
repair by down-regulating the homologous recombination protein RAD51. Here we investigated hypoxic
regulation of UBE2T, a ubiquitin ligase required in the Fanconi anemia (FA) DNA repair pathway.
Materials and methods: We analysed UBE2T expression by microarray, quantitative PCR and western blot
analysis in a panel of cancer cell lines as a function of oxygen concentration. The importance of this reg-
ulation was assessed by measuring cell survival in response to DNA damaging agents under normoxia or
hypoxia. Finally, HIF dependency was determined using knockdown cell lines and RCC4 cells which con-
stitutively express HIF1a.
Results: Hypoxia results in rapid and potent reductions in mRNA levels of UBE2T in a panel of cancer cell
lines. Reduced UBE2T mRNA expression is HIF independent and was not due to changes in mRNA or pro-
tein stability, but rather reﬂected reduced promoter activity. Exposure of tumor cells to hypoxia greatly
increased their sensitivity to treatment with the interstrand crosslinking (ICL) agent mitomycin C.
Conclusions: Exposure to hypoxic conditions down-regulates UBE2T expression which correlates with an
increased sensitivity to crosslinking agents consistent with a defective Fanconi anemia pathway. This
pathway can potentially be exploited to target hypoxic cells in tumors.
Crown Copyright  2011 Published by Elsevier Ireland Ltd. All rights reserved. Radiotherapy and
Oncology 101 (2011) 190–197Solid tumors frequently display extreme heterogeneities in oxy-
genation within their microenvironment which arise from poorly
developed vasculature [1]. From clinical studies it is evident that
hypoxia correlates with poor prognosis [2–5]. This is in part due
to the resistance of hypoxic cells to standard cancer treatments like
radio- and chemotherapy and therefore has stimulated efforts to
increase radiotherapy efﬁcacy by reducing the hypoxic fraction
[6,7]. In addition tumor hypoxia is associated with a more aggres-
sive disease. For example, patients with high levels of tumor hy-
poxia have a poor prognosis when treated with surgery alone.
Hypoxic tumors have also been associated with increased angio-
genesis, increased autophagy, pH regulation as well as with higher
metastatic and invasive potential [4,8–14]. Several mechanisms
have been demonstrated to contribute to the association of hypox-
ia with more aggressive disease. For example, both transient and
stable genetic changes can contribute to cellular adaptation to hy-011 Published by Elsevier Ireland L
ronto, ON, Canada M5G 2M9.
outers).poxia that promotes overall tumor growth [15,16]. The ﬁrst dem-
onstration of this mechanism was the selective outgrowth of p53
and apoptosis-deﬁcient cells cultured under repeated conditions
of hypoxia [17]. In addition to causing increased cell survival, resis-
tance to apoptosis in the hypoxia tolerant cells can contribute to
increased genetic instability and the potential for selection of even
more aggressive disease [18]. This is ampliﬁed by recent observa-
tions that hypoxia suppresses the expression of key proteins in-
volved in DNA mismatch repair (MMR) and homologous
recombination (HR) repair. The MMR proteins MLH1, MLH2 and
MSH6 are down-regulated under hypoxic conditions [19–22]. Like-
wise, several studies have shown that HR activity is impaired by
hypoxia and is associated with reduced expression of the HR repair
proteins RAD51, BRCA1 and BRCA2 [23–25]. Reduced RAD51 and
BCRA1 mRNA levels have been observed after prolonged anoxic
conditions (<0.02% O2 for 48 h) and could be attributed to E2F4/
p130 mediated transcriptional repression at the proximal pro-
moter regions of both genes [25,26]. Decreased RAD51 and BRCA1
protein levels have also been reported under moderate hypoxia
(0.2% O2 for 72 h). Interestingly, this was not due to decreasedtd. All rights reserved.
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Fig. 1. Hypoxia down-regulates UBE2T expression. (A) Analysis of UBE2T mRNA expression in MCF7, HT29 and DU145 cells during anoxia using Affymetrix gene arrays. (B)
Down-regulation of UBE2T mRNA levels after 8 and 16 h of anoxia determined by Q-PCR. (C) Oxygen dependency of UBE2T down-regulation on the mRNA level in MCF7 cells.
(D) UBE2T protein levels determined by western blotting at 21%, 1.0%, 0.2% and <0.02% O2 in MCF7 and HeLa cells. Indicated intensities of UBE2T were normalized to loading
control actin and expressed relative to 21% O2 control for each cell line independently. CA9 served as positive control for hypoxia.
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translation [24].
Fanconi anemia (FA) is a rare, recessive genetic disorder inwhich
patients exhibit congenital defects, bonemarrow failure and cancer
susceptibility [27,28]. Patients are diagnosed by their cellular phe-
notype of chromosomal instability and hypersensitivity to DNA
interstrand crosslinks (ICLs) induced by agents such as mitomycin
C or cisplatin. Thus far, 13 distinct complementation groups have
been identiﬁed in Fanconi anemia and the gene products cooperatein a common DNA repair pathway to remove ICLs. Inactivation of
these genes is not only found in Fanconi anemia but also in a variety
of cancers in the general population [29]. ICLs are very toxic lesions
in proliferating cells as they obstruct separation of DNA strands
necessary for replication and transcription. A crucial aspect in the
initiation of ICL repair by the FA pathway is carried out through
mono-ubiquitylation of FANCD2 and FANCI [30,31]. The core
complex, containing FANCA, B, C, E, F, G, L and M together with
the FA associated proteins FAAP24 and FAAP100, functions as a
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Fig. 2. Impaired UBE2T expression is due to decreased promoter activity. (A) UBE2T mRNA stability was determined using Q-PCR in MCF7 cells that were pre-exposed for 24 h
to 21% or 0.2% O2 and then treated for indicated times with actinomycin D (n = 3). (B) Protein synthesis was blocked using cycloheximide to assess UBE2T protein half-life
under aerobic conditions or after exposure to 0.2% O2 for 24 h. (C) UBE2T or CA9 promoter constructs were transiently cotransfected with pcDNA3-LacZ into HeLa cells.
Luciferase activity was measured relative to b-galactosidase expression after 24 h of 0.2% O2 after which fold induction was calculated for each construct.
192 Hypoxia suppresses the FA pathwaymulti-subunit E3 ubiquitin ligase [32,33]. This complex together
with the novel E2 conjugating enzyme UBE2T facilitates mono-
ubiquitylation of FANCD2 and FANCI [34]. The exact mechanistic
function of FANCD2 and FANCI ubiquitylation is not clear, however
it seems to serve as a targeting signal to DNA damage, as it retains
the complex on chromatin and colocalizes with DNA repair proteins
in distinct foci at sites of DNA lesions [30,35–40].
Here we show that the ubiquitin conjugating enzyme UBE2T is
rapidly down-regulated at both themRNA and protein levels during
hypoxia in a HIF independent manner. This down-regulation corre-
lated with an increased sensitivity to ICL inducing agents under
hypoxic conditions. Hypoxic inhibition of the FA pathway repre-
sents a novel mechanism for increased genetic instability in cancer,
but can also provide an opportunity for use of synthetic lethal ap-
proaches to selectively target hypoxic cells in aggressive tumors.
Materials and methods
Cell culture
The following cell lines were obtained from ATCC: HT29,
DU145, MCF7, MDA-MD-468, U373, HCT116, Hela, ME180 and
SiHa. All cell lines were grown according to ATCC instructions.
For hypoxic exposure cells were transferred into a MACS VA500
micro-aerophilic workstation. The atmosphere in the chamber
consisted of 5% H2, 5% CO2, the desired % O2, and residual N2. For
exposure to stress inducing agents cells were grown for 24 h in
deferoxamine (DFO).Microarray experiments
Microarray experiments were performed as previously de-
scribed [41]. In short, MCF7, DU145 and HT-29 and cells were
grown on glass dishes and exposed to 0, 1, 2, 4, 8, 16 or 24 h of hy-
poxia (<0.02% O2). Three independent experiments were per-
formed and equal amounts of total RNA from each biological
repeat were pooled and hybridized to Human Genome U133 Plus
2.0 Arrays. Genes with signal intensities lower than 100 on one
or more arrays were removed from the analysis.Plasmids and lentiviral work
Knock-down of UBE2T and HIF-1awas achieved using lentiviral
shRNA constructs TRCN0000004386, TRCN000000439 and
TRCN0000003808 (TRC consortium). Lentiviral particles were gen-
erated by co-transfection of 293T cells with packaging plasmids
pCMVdR8.74psPAX2 and pMD2.G together with shRNA vector
pLKO.1. Virus supernatant was harvested 48 and 72 h post trans-
fection. MCF7 cells were transduced with lentiviral supernatant
in the presence of 8 lg/ml polybrene. Infected cells were selected
for 2 days in 2 lg/ml puromycin containing media.RNA extraction and quantitative RT-PCR
RNA was isolated using Tri-reagent (Sigma) according to manu-
facturers’ instructions. RNA samples were reverse transcribed
using q-Script kit as described by manufacturer (Quantas).
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Fig. 3. UBE2T down-regulation in response to DFO treatment. MCF7 and HeLa cells
were treated with DFO for 24 h after which UBE2T and CA9 mRNA (A) or protein
levels (B) were determined.
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cycler using SYBR green (Quantas). Gene expression was normal-
ized to RPL13A under hypoxic or anoxic conditions and to b-actin
following treatment with DFO, as the expression of these genes is
constant and well within the dynamic range of the Q-PCR under
the particular conditions. For determination of UBE2T mRNA half
life cells were treated with 5 lg/ml actinomycin D (Sigma) for
the indicated times.Western blot analysis
Cells were washed twice with cold PBS and scraped in 50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late and 0.1% SDS supplemented with protease inhibitors (Roche).
After centrifugation at 10,000 g supernatants were boiled in Lae-
mmli buffer for 10 min and proteins were resolved by SDS–PAGE.
Proteins were subsequently transferred onto PVDF membranes
and blocked for 1 h in TBS containing 0.05% Tween-20 (TBS-T) sup-
plemented with 5% skim milk powder. Membranes were probed
overnight at 4 C with antibodies directed against UBE2T (Abnova),FANCD2 (Santa-Cruz), CA9 (M75, or b-actin (Sigma). Bound anti-
bodies were visualized using HRP-linked secondary antibodies
(GE healthcare) and ECL luminescence (Pierce).Luciferase reporter constructs
A 2.2 kb fragment from the 50 ﬂanking region of the UBE2T gene
was ampliﬁed using the following primers; UBE2T_F 50CGATG
GTACCCCCACCAGTTAACATACCCC 30, UBE2T_R 50CGATAAGCTTC
AGTGGCTTTTCTAAGGCTCTCC 30 and subsequently cloned into
pGL2-basic vector (Promega, Madison, WI). MCF7 cells were tran-
siently co transfected with the UBE2T or CA9 [42] promotor con-
structs and pcDNALacZ using Lipofectamine (Invitrogen) as
described by the manufacturer. Transfected cells were sub cultured
16 h post transfection, exposed to hypoxia and ﬁnally harvested
48 h after transfection. Luciferase and b-galactosidase activity was
measured using a commercial kit (Amplied biosystems) and mea-
sured on the Fluorstar Optima platereader (BMG Labtech).Clonogenic assays
Cells were exposed to 21% or <0.02% O2 for 24 or 48 h and sub-
sequently treated with 1 lg/ml MMC for 1 h at 21% O2. After the
treatment cells were trypsinized and plated for clonogenic survival
at a range of 200–10,000 cells per 6-cm dish in triplicate. Subse-
quently cells were grown for 14 days and resulting colonies were
stained with methylene blue (Sigma). Colonies of at least 50 cells
were counted.Statistical analysis
Unpaired Student t-test was used to test signiﬁcance between
populations. p < 0.05 was considered signiﬁcant. Points and error
bars plotted in graphs of all ﬁgures represent the mean ± standard
deviation.Results
Hypoxia down-regulates expression of UBE2T
As part of other ongoing studies, we have assessed changes in
the transcriptomes of several cancer cell-lines as a function of time
following exposure to anoxic conditions (<0.02% O2). DU145, MCF7
and HT29 cells were exposed to these conditions for 1, 2, 4, 8, 12,
16 and 24 h to identify both increases and decreases in gene
expression associated with acute and chronic anoxia. One of the
most rapid and strongly repressed transcripts identiﬁed in this
study encodes the E2 ubiquitin conjugase, UBE2T. UBE2T mRNA
levels were signiﬁcantly down-regulated in all three cell lines with
similar kinetics, reaching approximately 50% within 8 h of anoxic
exposure. At 24 h of anoxia UBE2T mRNA levels were reduced to
10% of starting values in normoxic controls (Fig. 1A). The ob-
served down-regulation of UBE2T mRNA levels is selective as the
expression of the majority of genes on the array remains un-
changed under these conditions.
To conﬁrm these results, quantitative reverse transcription-PCR
analysis was performed on a panel of additional cell-lines consist-
ing of 4 breast cancer lines, 3 cervix cancer lines and 1 glioma line.
Signiﬁcant down-regulation of UBE2T was observed after 8 h of
anoxic conditions in all cell-lines except for ME-180 and U373.
After 16 h of anoxic exposure, UBE2T was down-regulated in all
cell lines and most strongly in MCF7, T47D and HeLa cells
(Fig. 1B). UBE2T mRNA levels were normalized to RPL13A as
described in the materials and methods. The normoxic levels of
UBE2T were similar across the panel of eight lines.
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194 Hypoxia suppresses the FA pathwayExposure to very low oxygen conditions can inﬂuence cell death
by inducing apoptosis, or by decreasing cell proliferation and
altering cell-cycle distribution, both of which could potentially be
inﬂuencing UBE2T expression. To investigate if UBE2T mRNA
expression is also decreased under more moderate hypoxic condi-
tions that do not induce these effects, we compared UBE2T mRNA
levels of MCF7 cells exposed to <0.02%, 0.2% or 1% O2 for 8 or 24 h.
After 8 h of exposure, UBE2T levels were decreased substantially
only in cells exposed to <0.02% O2, whereas all three conditions sig-
niﬁcantly reduced UBE2T mRNA levels following 24 h exposure. At
0.2% hypoxia, which causes no signiﬁcant change in cell-cycle or
cell survival in these cells (data not shown), UBE2T mRNA was
down-regulated to a similar extent to that observed under anoxia
after 24 h (Fig. 1C). In agreement with the down-regulation at
the mRNA level, we observed strong decreases in UBE2T protein
levels in MCF7 and HeLa after 24 h exposure to 1%, 0.2% and
<0.02% O2 (Fig. 1D).UBE2T is down-regulated by transcriptional repression
Given the relatively rapid drop in mRNA levels, we investigated
whether the decreased expression could be explained by a change
in mRNA stability. To this end we treated MCF7 cells with the tran-
scriptional inhibitor actinomycin D for different durations undernormoxic or hypoxic conditions and subsequently measured
mRNA abundance to determine transcript half-life. Under normox-
ic conditions UBE2T mRNA half-life was estimated to be 3 h, and
under hypoxia this value showed a small increase to 5 h (Fig. 2A).
This suggests that UBE2T is not preferentially degraded under hyp-
oxic conditions and if anything is somewhat more stable than un-
der normoxic conditions (Fig. 2A).
The biological impact of a rapid change in mRNA abundance is
inﬂuenced by the relative stability of the protein encoded by that
particular mRNA, particularly in the case for suppressed genes.
The data in Fig. 1 suggest that, at least within 24 h, the drop in
mRNA level is sufﬁcient to affect protein levels signiﬁcantly, sug-
gesting that UBE2T protein may have a relatively short half-life.
We were unaware of any published studies on the half-life of
UBE2T protein and so we assessed this in cells under normoxic
or following 24 h of hypoxic (0.2%) conditions using cyclohexamide
(CHX) treatment for various periods of time (Fig. 2B). The data indi-
cate that UBE2T does indeed have a relatively short half-life under
normoxic conditions of 7.5 h, consistent with the measured pro-
tein loss observed within 24 h. The half-life could not be deter-
mined following pre-exposure to hypoxia, because starting levels
were too low. However, the fact that protein levels were reduced
in the hypoxia treated samples to undetectable levels following
6 h of cyclohexamide indicates that the half-life is similar or
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C.H.M.A. Ramaekers et al. / Radiotherapy and Oncology 101 (2011) 190–197 195shorter than that measured in normoxic samples. Consequently,
suppression of UBE2T mRNA during hypoxia has a rapid impact
on protein availability.
These data suggest that differences in UBE2T expression are
likely due to changes in transcription. To test changes in UBE2T
promoter activity more directly, we cloned a 2 kb fragment up-
stream of the transcriptional start site for UBE2T into a luciferase
reporter construct. Luciferase activity was measured after transient
transfection of this construct and subsequent exposure to either
24 h of 21% or 0.2% O2. Luciferase activity driven from the UBE2T
promoter was decreased to 68% under hypoxic conditions com-
pared to normoxia (Fig. 2C). In contrast, a CA9 promoter containing
construct showed a 23-fold increase in luciferase activity upon hy-
poxia. Together, these data imply that the reduction of UBE2T is
due primarily to a decrease in transcription, and that this effect
rapidly inﬂuences protein levels due to a relatively high turnover
of the protein.0.0001
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Fig. 5. Reduced UBE2T expression and hypoxia sensitizes cells to the interstrand
crosslinking agent mitomycin C. (A) Knockdown efﬁciency of UBE2T using shRNA
was determined by western blot analysis and its effect on clonogenic survival was
assessed following treatment with 1 lg/ml MMC for 1 h. (B) Cells were exposed toThe effect of DFO on UBE2T expression
To investigate whether UBE2T repression is dependent on the
transcription factor HIF1a (hypoxia inducible factor 1a) we treated
MCF7 and HeLa cells with DFO (deferoxamine) for 24 h. DFO is a
metal chelating agent, which is known to stabilize HIF1a and
HIF2a by inhibiting the HIF prolyl hydroxylases (PHD1–3) whose
activity is required for HIF1a and HIF2a degradation [43]. As ex-
pected, DFO treatment led to strong induction of the HIF-target
gene carbonic anhydrase 9 (CA9) at the mRNA and protein levels
in both cell lines (Fig. 3A and B). Consistent with a role for HIF in
its regulation, UBE2T mRNA and protein levels were signiﬁcantly
decreased in both cell-lines following DFO treatment to a similar
extent as to that following hypoxic exposure (Fig. 3A and B).<0.02% O2 for 24 or 48 h and subsequently treated with 1 lg/ml MMC for 1 h at 21%
O2. Afterward cells were seeded for clonogenic survival. Plating efﬁciency for all
treatments was determined after 14 days and surviving fraction was calculated.UBE2T down-regulation is HIF independent
To assess the requirement for the HIF transcription factor more
directly, we established stable MCF7 cells expressing shRNA
against HIF1a. Knockdown of HIF1a was conﬁrmed at both the
mRNA and protein levels, as well as by assessing induction of its
transcriptional target CA9 (Fig. 4A and B). The induction of CA9
was severely inhibited in cells expressing the shRNA against HIF1a.
In contrast, HIF1a knockdown did not affect the down-regulation
of UBE2T observed under hypoxic conditions (Fig. 4A and B). Also,
knockdown of HIF2a or HIF1b did not affect UBE2T levels under
hypoxic conditions (Supplementary Fig. 1). To assess HIF depen-
dency in a different model, we utilized RCC4 renal cell carcinoma
cells which lack functional VHL leading to constitutive expression
of HIF1a and HIF2a. RCC4 cells displayed high levels of CA9 com-
pared to RCC4 cells reconstituted with VHL (Fig. 4C). However,
UBE2T expression was similar in both VHL deﬁcient and proﬁcient
cells (Fig. 4C). Together these data robustly demonstrate that
UBE2T down-regulation does not correlate with HIF activity.Hypoxia sensitizes cells to the interstrand crosslinking agent MMC
UBE2T is the E2 ubiquitin conjugase required for ubiquitylation
of FANCD2 and activation of the Fanconi anemia pathway. Since
this pathway is essential for the repair of interstrand crosslinks,
we ﬁrst assessed clonogenic survival of cells with UBE2T knock-
down after treatment with MMC (Fig. 5A). UBE2T knockdown
markedly sensitized cells to MMC, so next we tested if hypoxic
exposures sufﬁcient to down-regulate UBE2T would similarly
cause sensitization to MMC. Indeed, we found that cells exposed
to 24 or 48 h of < 0.02% O2 were signiﬁcantly more sensitive to
treatment with 1 lg/ml MMC as assessed by clonogenic survival
(Fig. 5B). These data are consistent with a hypoxia induced defectin the FA pathway under hypoxic conditions and an increased
sensitization of cells to MMC.
Discussion
Solid tumors are characterized by poor and heterogeneous oxy-
genation [1], features associated with an aggressive phenotype, ge-
netic instability and poor response to therapy [2–5]. Several
mechanisms can contribute to this adverse tumor biology includ-
ing a reduction in DNA repair activity [18,44]. In particular, previ-
ous studies have shown that proteins involved in homologous
recombination DSB repair are down-regulated during hypoxic con-
ditions [24,45]. In this study, we demonstrate that the E2 ubiquitin
conjugating enzyme UBE2T, a key protein in the Fanconi anemia
pathway, is transcriptionally repressed under hypoxia. Rapid
reductions in UBE2T expression were due to a reduction in pro-
moter activity mediated by an element within 2 kb of the tran-
scriptional start site. Repression occurred rapidly and was
observed in a large panel of cancer cell lines and at a wide range
of oxygen concentrations. Importantly, the repression of UBE2T
transcription translated into substantial reductions in protein lev-
els, due to the relatively short half-life of the UBE2T protein which
was determined to be 7.5 h. The hypoxic exposures required to
observe changes in UBE2T protein levels, and thus inﬂuence DNA
repair, are relatively short compared with that previously demon-
strated to cause RAD51 down-regulation. UBE2T protein levels
were reduced to almost undetectable levels following exposure
to 24 h of 0.2% or < 0.02% O2, whereas down-regulation of RAD51
was reported only after 72 h of 0.2% or 48 h of <0.02% oxygen
[24,45].
196 Hypoxia suppresses the FA pathwayThe ubiquitin conjugase UBE2T mediates ubiquitylation of the
Fanconi anemia (FA) proteins FANCD2 and FANCI in concert with
the multi-subunit FA ‘‘core-complex’’ E3 ubiquitin ligase [30,31,
35,46]. These ubiquitylation events are essential for activation of
the FA-pathway required for the repair of interstrand DNA cross-
links (ICLs). Consistent with a defective FA-pathway we found that
hypoxic cells with reduced UBE2T levels were markedly sensitized
to MMC treatment (Fig. 5B). These data provide strong correlative
evidence linking down-regulation of UBE2T during hypoxia with
sensitivity to cross linking agents. However, the direct contribution
of UBE2T to the sensitivity is not yet known, and it remains possi-
ble that unrelated effects of hypoxia could contribute to this effect.
For example, the increased sensitivity of cells after 24 h of anoxia
in Fig. 5B are consistent with a previous study by Chan et al. that
showed enhanced cell death in response to treatment with cross-
linking agents after exposure to more chronic hypoxia (72 h 0.2%
oxygen), an effect which was correlated with loss of RAD51 at this
time point [24]. It will be interesting to determine the relative con-
tribution of UBE2T repression to the increased sensitivity of hyp-
oxic cells to MMC.
HIF-1a stabilization occurs through inhibition of prolyl-hydrox-
ylases, which under oxic conditions stimulate VHL mediated ubiq-
uitylation of HIF-1a, thereby targeting it for degradation by the
proteasome [47]. Despite the fact that UBE2T was down-regulated
in response to the iron chelator DFO, we established that decreased
UBE2T expression was not dependent on HIF activity, as knock-
down of HIF-1a, HIF-2a or HIF-1b had no effect on UBE2T repres-
sion upon hypoxia (Figs. 3 and 4 and Supplementary Fig. 1). Using
renal cell carcinoma (RCC) cells, which often experience high levels
of constitutive HIF expression due to inactivation of the tumor sup-
pressor VHL, we conﬁrmed in another way that UBE2T repression
is not associated with HIF activity (Fig. 4C). Besides deregulating
the prolyl-hydroxylases that regulate HIF-1a stability, both DFO
and hypoxia also affect the recently identiﬁed Jumonji family of
hydroxylases [48]. These iron and oxygen dependent enzymes
modulate gene expression by histone tail modiﬁcations. We spec-
ulate that inhibition of this family of enzymes could affect UBE2T
promoter activity through increased methylation of histone marks
that lead to epigenetic silencing.
Our data contributes to the growing evidence that DNA repair
pathways are compromised under hypoxic conditions. These DNA
repair defects present new opportunities to target otherwise resis-
tant hypoxic cells. One example that has received recent attention
is the synthetically lethal effect that PARP-inhibitors have on HR
deﬁcient cells due to BRCA1 or BRCA2 mutations. This concept of
synthetic lethality can also be applied in a contextual setting to
hypoxic tumors which have HR defects due to down-regulation
of important HR proteins [44]. The data presented here, suggest
an additional contextual synthetic lethal combination of hypoxia
with agents that engage the FA pathway, and it will be interesting
to determine if ICL agents have preferential activity against aggres-
sive hypoxic tumors in patients. Ultimately this information might
increase treatment efﬁcacy and patient outcome.
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